Pyxis Oncology, Inc. (PYXS) vs Sutro Biopharma, Inc. (STRO)

Pyxis Oncology, Inc. and Sutro Biopharma, Inc. are both Biotechnology companies. Pyxis Oncology, Inc. and Sutro Biopharma, Inc. are of similar size ($260.5M and $250.2M). Pyxis Oncology, Inc. has the higher net margin (0.00% vs −395.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Pyxis Oncology, Inc. leads on 6 and Sutro Biopharma, Inc. on 5.

Valuation

Metric PYXS STRO Biotechnology median
P/E n/m n/m 7.88
P/S n/m 5.79 11.47
P/B 16.00 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 2.83 10.73
Earnings yield (49.30%) (108.41%) (28.84%)
Free cash flow yield (37.11%) (54.99%) (23.03%)

Profitability

Metric PYXS STRO Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (319.57%) 0.00%
Net margin 0.00% (395.25%) 0.00%
Free cash flow margin 0.00% (318.63%) 0.00%
Return on equity (179.10%) 266.76% (57.72%)
Return on assets (99.62%) (79.08%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric PYXS STRO Biotechnology median
Revenue growth (TTM) — (56.25%) 5.64%
EPS growth (last fiscal year) 3.03% 24.02% —
Revenue growth, 5-year CAGR — 19.12% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PYXS STRO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.34 3.32 4.73
Net debt to EBITDA 0.82 0.92 0.96

Dividend

Metric PYXS STRO Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric PYXS STRO Biotechnology median
Market cap 250.22m 260.49m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack